Mobidiag Oy, a pioneering company in the field of molecular diagnostics, is headquartered in Finland (FI) and operates extensively across Europe and beyond. Founded in 2009, Mobidiag has established itself as a leader in the development of innovative diagnostic solutions, particularly in the areas of infectious diseases and antibiotic resistance. The company’s core offerings include the Novodiag® and Amplidiag® product lines, which are distinguished by their rapid, accurate testing capabilities. These products leverage cutting-edge technology to provide healthcare professionals with timely and reliable results, enhancing patient care and treatment outcomes. With a strong commitment to research and development, Mobidiag has achieved significant milestones, positioning itself as a trusted partner in the diagnostics industry. Its unique approach to molecular testing has garnered recognition, making it a key player in the global market for diagnostic solutions.
How does Mobidiag Oy's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Mobidiag Oy's score of 64 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mobidiag Oy, headquartered in Finland (FI), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Hologic, Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. Mobidiag Oy has not established its own reduction targets or climate pledges, nor does it report any specific initiatives aimed at reducing carbon emissions. However, it is important to note that the company may align with broader sustainability goals set by Hologic, Inc., which may include initiatives related to the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). As a subsidiary, Mobidiag Oy's climate commitments and performance may reflect the strategies and targets of Hologic, Inc., although specific details on these initiatives are not provided. The absence of direct emissions data and reduction targets suggests that Mobidiag Oy is in the early stages of developing its climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
Mobidiag Oy's Scope 3 emissions, which decreased by 10% last year and decreased by approximately 10% since 2020, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 61% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mobidiag Oy has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.